New software predicts the results of an oncological surgery

The software will be able to predict whether ovarian cancer surgery will involve the complete removal of the entire tumor from the abdominal cavity

A research team of the Multidisciplinary Unit of Abdomen-Pelvic Oncology Surgery (UMCOAP) from the foundation FISABIO and the Department of Medicine of the University Jaume I (UJI) have designed a software capable of predicting whether cancer surgery ovary will involve the complete removal of the entire tumor from the abdominal cavity.

Antoni Llueca, a physician at UMCOAP, explained that the increase in patient survival “is related to the removal of the tumor by the surgical team.” Therefore, this software, “which is still a mathematical model, is able to predict when the surgery will be optimal.

As reported in a statement, “optimal” surgery involves “completely” removing the tumor from the pelvic cavity in a patient with advanced ovarian cancer. On the other hand, there is talk of “suboptimal” surgery when it has not been able to eradicate completely. This situation goes hand in hand with a high morbidity percentage and also compromises the patient’s prognosis.

Validated in 110 patients

The software, which has a “higher” sensitivity to other predictors, has been validated in 110 patients with advanced ovarian cancer in Castellón, Spain. Its use allows the surgical team to make the right decisions and reduce the number of suboptimal surgeries. In addition, the software, which is presented as an App, adapts to the evolution of the surgical team over time “modifying the results based on the improvement of the equipment and the results obtained by the surgical team during its use”.

They have also pointed out that one of the “most outstanding” advantages of the software is that it can be adapted “easily” to the conditions of each medical team and with it it is possible to predict “in an optimal way which patients can benefit from surgery or which ones should start with a chemotherapy treatment to decrease the tumor burden.”

The system is registered in the Patent Bank of the Generalitat Valenciana under the ownership of the FISABIO Foundation and the UJI of Castellón.

Source: dpa

Comments are closed.